We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Cost analysis of an active surveillance strategy for Clostridium difficile using an agent-based simulation
© Rubin et al; licensee BioMed Central Ltd. 2015
- Published: 16 June 2015
- Clostridium Difficile Infection
- Active Surveillance
- Hand Hygiene
- Clostridium Difficile
- Personal Protective Equipment
Clostridium difficile (CD) is one of the most common nosocomial infections in the United States. Rapid identification and isolation of hospitalized patients with CD colonization or infection is critical to preventing transmission.
This work assesses the potential impact of an active surveillance (AS) strategy for CD via admission testing on overall costs and infections.
We designed an agent-based simulation of nosocomial CD transmission with static and dynamic components including: patients, healthcare workers (HCW), and rooms; patient admission, discharge, and transfer; interactions between HCW and patients; contamination of rooms by patients shedding CD; HCW hand carriage and removal via hand hygiene or prevention via personal protective equipment; and patient acquisition of CD following contact with contaminated rooms or HCW. Model parameters were derived from local data, literature where available, and expert opinion. The model was calibrated against local data and validated internally and externally.
Two scenarios with varying CD importation prevalence were simulated 60 times each over a one-year period. One scenario reflected the usual strategy of no admission testing, while another reflected an AS strategy with CD testing of all patients upon admission. Importation prevalence was varied in a sensitivity analysis from 0%>30%. Cost input parameters were obtained from the literature.
At moderate to high levels of CD importation (≥9%) an AS strategy is cost-saving overall, reducing costs by between $10 and $20 per patient, owing primarily to CD infections prevented. The cost savings plateaued at an importation prevalence above 12%. At low CD importation (<6%), the AS strategy costs more than no surveillance, though costs per patient are low. Up to 38 CD infections per 10,000 patient-days could be prevented with an AS strategy.
Despite the additional cost of testing and isolation, an inpatient AS strategy for CD may be cost-saving through the prevention of CD transmissions and infections. Given reported CD admission prevalence and infection mortality rates, further consideration of this strategy may be worthwhile.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.